tbuckley/cabot-search huggingface dataset:
Prostate Cancer Risk and Vitamin E—Reply
Authors: Eric A. Klein
Journal: JAMA (2012)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mouse lysocardiolipin acyltransferase controls the development of hematopoietic and endothelial lineages during in vitro embryonic stem-cell differentiation
Authors: Chengyan Wang, Patrick W. Faloon, Zhijia Tan, Yaxin Lv, Pengbo Zhang, Yu Ge, Hongkui Deng, Jing-Wei Xiong
Journal: Blood (2007)
MicroRNA-31 controls G protein alpha-13 (GNA13) expression and cell invasion in breast cancer cells
Authors: Suhail Ahmed Kabeer Rasheed, Cui Rong Teo, Emmanuel Jean Beillard, P Mathijs Voorhoeve, Wei Zhou, Sujoy Ghosh, Patrick J Casey
Journal: Molecular Cancer (2015)

Gα13 (GNA13) is the α subunit of a heterotrimeric G protein that mediates signaling through specific G protein-coupled receptors (GPCRs). Our recent study showed that control of GNA13 expression by specific microRNAs (miRNAs or miRs) is important for prostate cancer cell invasion. However, little is known about the control of GNA13 expression in breast cancers. This project was carried out to determine (i) whether enhanced GNA13 expression is important for breast cancer cell invasion, and (ii) if so, the mechanism of deregulation of GNA13 expression in breast cancers.To determine the probable miRNAs regulating GNA13, online miRNA target prediction tool Targetscan and Luciferase assays with GNA13-3'-UTR were used. Effect of miRNAs on GNA13 mRNA, protein and invasion was studied using RT-PCR, western blotting and in vitro Boyden chamber assay respectively. Cell proliferation was done using MTT assays.Overexpression of GNA13 in MCF-10a cells induced invasion, whereas knockdown of GNA13 expression in MDA-MB-231 cells inhibited invasion. Expression analysis of miRNAs predicted to bind the 3'-UTR of GNA13 revealed that miR-31 exhibited an inverse correlation to GNA13 protein expression in breast cancer cells. Ectopic expression of miR-31 in MDA-MB-231 cells significantly reduced GNA13 mRNA and protein levels, as well as GNA13-3'-UTR-reporter activity. Conversely, blocking miR-31 activity in MCF-10a cells induced GNA13 mRNA, protein and 3'-UTR reporter activity. Further, expression of miR-31 significantly inhibited MDA-MB-231 cell invasion, and this effect was partly rescued by ectopic expression of GNA13 in these cells. Examination of 48 human breast cancer tissues revealed that GNA13 mRNA levels were inversely correlated to miR-31 levels.These data provide strong evidence that GNA13 expression in breast cancer cells is regulated by post-transcriptional mechanisms involving miR-31. Additionally our data shows that miR-31 regulates breast cancer cell invasion partially via targeting GNA13 expression in breast cancer cells. Loss of miR-31 expression and increased GNA13 expression could be used as biomarkers of breast cancer progression.
Mutations in the phospholipid remodeling gene SERAC1 impair mitochondrial function and intracellular cholesterol trafficking and cause dystonia and deafness
Authors: Saskia B Wortmann, Frédéric M Vaz, Thatjana Gardeitchik, Lisenka E L M Vissers, G Herma Renkema, Janneke H M Schuurs-Hoeijmakers, Wim Kulik, Martin Lammens, Christin Christin, Leo A J Kluijtmans, Richard J Rodenburg, Leo G J Nijtmans, Anne Grünewald, Christine Klein, Joachim M Gerhold, Tamas Kozicz, Peter M van Hasselt, Magdalena Harakalova, Wigard Kloosterman, Ivo Barić, Ewa Pronicka, Sema Kalkan Ucar, Karin Naess, Kapil K Singhal, Zita Krumina, Christian Gilissen, Hans van Bokhoven, Joris A Veltman, Jan A M Smeitink, Dirk J Lefeber, Johannes N Spelbrink, Ron A Wevers, Eva Morava, Arjan P M de Brouwer
Journal: Nature Genetics (2012)
Government clarifies long term NHS care
Authors: J Warden
Journal: BMJ (1994)

Criticism that the NHS is neglecting the long term health care of elderly people has prompted the Department of Health to clarify its responsibilities. As a result, health authorities are being told to reassess their provision for long term health care. But the Labour opposition and voluntary organisations say that many ambiguities remain.

Draft guidance issued for consultation by the NHS Executive requires health authorities to make “appropriate provision” and to draw up local criteria for eligibility. Some authorities …
Age-specific oncogenesis: the genetics of cancer susceptibility.
Authors: D Malkin
Journal: Environmental Health Perspectives (1995)

Cancer is considered to be a multifactorial disease in which a host cell is transformed from normal to malignant as a result of complex interactions of external (environmental) stimuli and cancer-predisposing or cancer-suppressing genes. Although certain chemical carcinogens and ionizing radiation are known to cause specific alterations at the level of the gene, other correlations are less clear. Not infrequently, cancer is found to aggregate in families in an apparently nonrandom fashion. It has been through the study of such families that our understanding of the genetic events leading to cancer has developed. Both common and rare tumors may occur together in familial-cancer families. Frequently, tumors occur at an earlier age than one would expect in the general population; often, multiple tumors of different organs develop in a particular affected family member. Recent advances in the genetics of familial cancer syndromes have led to the possibility to perform genetic testing on unaffected relatives who might carry a genetic defect that predisposes them to cancer. Complex ethical, social, and legal implications arise from these new technical advances.
That Which Is a Chore Isn't
Authors: Howard J. Bennett
Journal: JAMA (1985)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Botulinum toxin type A reduces histamine-induced itch and vasomotor responses in human skin
Authors: P. Gazerani, N.S. Pedersen, A.M. Drewes, L. Arendt-Nielsen
Journal: British Journal of Dermatology (2009)

Journal Article Botulinum toxin type A reduces histamine‐induced itch and vasomotor responses in human skin Get access P. Gazerani, P. Gazerani Center for Sensory‐Motor Interaction, Department of Health Sciences and Technology, Aalborg University, DK‐9220 Aalborg, Denmark Search for other works by this author on: Oxford Academic Google Scholar N.S. Pedersen, N.S. Pedersen Center for Visceral Biomechanics and Pain, Department of Gastroenterology, Aalborg University Hospital, Aalborg, Denmark Search for other works by this author on: Oxford Academic Google Scholar A.M. Drewes, A.M. Drewes Center for Sensory‐Motor Interaction, Department of Health Sciences and Technology, Aalborg University, DK‐9220 Aalborg, DenmarkCenter for Visceral Biomechanics and Pain, Department of Gastroenterology, Aalborg University Hospital, Aalborg, Denmark Search for other works by this author on: Oxford Academic Google Scholar L. Arendt‐Nielsen L. Arendt‐Nielsen Center for Sensory‐Motor Interaction, Department of Health Sciences and Technology, Aalborg University, DK‐9220 Aalborg, Denmark Correspondence: Lars Arendt‐Nielsen. E‐mail: LAN@hst.aau.dk http://www.smi.hst.aau.dk/members/lan/ Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 161, Issue 4, 1 October 2009, Pages 737–745, https://doi.org/10.1111/j.1365-2133.2009.09305.x Published: 01 October 2009
Low Risk Ductal Carcinoma In Situ (DCIS) Treated with Breast Conserving Surgery &amp; Accelerated Partial Breast Irradation (APBI): Comparison of the Mammosite Registry Trial with Intergroup Study E5194.
Authors: S. Goyal, F. Vicini, P. Beitsch, M. Keisch, J. Jeruss, M. Lyden, B. Haffty
Journal: Cancer Research (2009)

Abstract Purpose/Objective(s): Recent data from Intergroup Study E5194 prospectively defined a low risk subset of ductal carcinoma in situ (DCIS) patients where radiation therapy was omitted after local excision alone. At 5 years, they found a 6.8% ipsilateral breast event rate (IBTR) in selected low/intermediate grade (LIG) patients and a 13.7% IBTR in selected high grade (HG) patients. The purpose of our study was to determine the IBTR in DCIS patients treated on the American Society of Breast Surgeons (ASBrS) MammoSite® Breast Brachytherapy registry trial who met the criteria of E5194 treated with local excision and adjuvant APBI.Material/Methods: A total of 194 patients with DCIS were treated between 2002 and 2004 on the Mammosite registry trial; of these, 69 patients met the enrollment criteria for E5194: 1. LIG: low to intermediate grade with a pathological size &amp;gt; 0.3cm but &amp;lt; 2.5cm and margins &amp;gt;3mm (n=40) or 2. HG: high grade, pathological size &amp;lt;1cm and margins &amp;gt;3mm (n=29). All patients were treated with lumpectomy followed by adjuvant APBI (34 Gy in 3.4 Gy fractions). Median follow-up for surviving patients was 50.7 months (range, 0-73.4). Hormonal therapy was given to 51% of these patients (compared to 30% of patients on E5194). The clinical-pathologic data and long term outcomes for each patient were entered into a database for statistical analysis using SAS (v 8.2).Results: The median age of the entire cohort was 62.5 years. In the LIG cohort, the median size was 0.8cm. In the HG cohort, the median size was 0.6cm. In the LIG cohort, the 5-year IBTR was 0%, compared to 6.8% at 5 years in E5194. In the HG cohort, the 5-year IBTR was 5.3% compared to 13.7% at 5years in E5194. The overall the 5-year IBRT was 2% and there were no cases of elsewhere or regional failures in the entire cohort. The 5-year contralateral breast event rate was 0% and 5.6% in LIG and HG patients, respectively (compared to 3.5% and 4.2%, respectively, in E5194). The 5-year disease free survival and overall survival rate was 92.4% and 96.5%, respectively. In all patients with DCIS (n=194) treated with Mammosite on the registry trial, the 5-year actuarial IBTR, DFS, and OS was 3.1%, 93.8% and 98.2%, respectively.Conclusion: Adjuvant accelerated partial breast irradiation using Mammosite is a relatively convenient form of radiotherapy which shortens treatment time to 1 week. This study found that patients who met the criteria of E5194 treated with APBI had extremely low rates of recurrence (0% vs. 6.8% in the low to intermediate grade and 5.3% vs. 13.7% in the high grade). We conclude that all patients with DCIS who were eligible for E5194 have appreciable benefit from adjuvant APBI. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 951.
Lack of insurance, reassurance, and safety assurance
Authors: Douglas Kamerow
Journal: BMJ (2007)

Among industrialized countries, only the United States lacks universal health insurance for its residents. Instead we have a patchwork quilt of coverage, sponsored by the Federal government, individual states, employers, and individuals. Karen Davis documents the number of uninsured people in America, analyzes the problems associated with lack of coverage, and explores some possible remedies (doi: 10.1136/bmj.39091.493588.BE). About 16% of Americans are uninsured, almost 50 million people. Unsurprisingly, the uninsured are disproportionately poor, and when they do receive …
Blended Payment Methods in Physician Organizations Under Managed Care
Authors: James C. Robinson
Journal: JAMA (1999)

Independent practice associations (IPAs) are developing new methods of physician reimbursement to balance the objectives of encouraging individual productivity and clinical cooperation. The economic literature on payment incentives, derived from nonhealth industries, predicts that methods blending elements of fee-for-service and capitation will outperform exclusive reliance on either form of payment.To identify emerging payment methods within IPA physician groups that contract with managed care organizations.Case studies of 7 large IPAs in the San Francisco, Calif, metropolitan region that served 826000 health maintenance organization (HMO) patients during the summer and fall of 1998.Payment methods of IPAs for primary care physicians, specialists, and physicians grouped by specialty department within the overall IPA structure.All the IPAs contracted with multiple HMOs for the full range of primary and specialty care physicians' services but paid member physicians using methods that blended elements of fee-for-service and subcapitation. For primary care, most IPAs used monthly capitation adjusted for patient age, sex, and selected diagnoses, supplemented with fee-for-service payment for a wide range of visits and procedures, including patient visits in subacute, skilled nursing facility, emergency department, or home settings; for preventive care services; for office procedures requiring expensive supplies; and, most importantly, for borderline primary care procedures that either could be performed directly or referred to specialty care. All the IPAs paid specialty departments on a capitated basis and delegated to the departments responsibility for allocating the budget among individuals. Allocation mechanisms for individual specialists included adjusted fee-for-service, referral-based capitation, and blends of both.Our results and case studies indicate that IPAs are developing payment methods that blend elements of fee-for-service and capitation in innovative ways for primary care and specialty physicians.
Abstract 1209: Detection of EGFR T790M mutation in non-small-cell lung cancer patients using colony hybridization assay
Authors: Yoshihiko Fujita, Kenichi Suda, Hideharu Kimura, Kazuko Matsumoto, Tokuzo Arao, Tomoyuki Nagai, Hidetoshi Hayashi, Kazuyuki Furuta, Hiroaki Kato, Nagahiro Saijo, Yasushi Yatabe, Tetsuya Mitsudomi, kazuto Nishio
Journal: Cancer Research (2012)

Abstract Non-small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations (deletion in exon 19 or L858R) show a dramatic response to EGFR tyrosine kinase inhibitors (EGFR TKIs). However, most patients have a relapse within 1 year after the initiation of therapy. An EGFR secondary mutation T790M has been observed in approximately 50 % of such lung cancers that acquire resistance to EGFR TKIs. A critical question is whether the T790M mutation occurs as a result of treatment with EGFR TKIs or whether it exists prior to treatment and is selected during the course of therapy. However, its assessment can be challenging due to limited tissue availability and low sensitivity of the previously available methods. Here, we sought to detect the T790M using colony hybridization (CH) assay. This assay is able to detect mutant allele of 0.01 % in the background of wild-type allele. We assessed the T790M mutation in pretreatment specimens from 39 EGFR-TKI-treated patients with activating EGFR mutations. The T790M mutation was detected by CH in 31 of 39 patients (79 %). Median time to treatment failure (TTF) was 9 months in patients with pretreatment T790M, whereas it was 7 months in patients without the T790M mutation (P = 0.44). When we subdivided the patients with T790M into a strong and a modest positive subgroups in terms of the frequency of positive signals observed by our colony hybridization technique, seven patients with strong positivity had a TTF significantly longer than 8 patients without T790M (P = 0.0097) and 24 patients with modest positivity (P = 0.0019). Thus, the use of our highly sensitive method showed that a subgroup of patients with the EGFR mutation harbor rare T790M alleles before exposure to EGFR TKIs. However, contrary to our expectation, such patients had longer TTF. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1209. doi:1538-7445.AM2012-1209
Dichotomous Haplotypic Lineages of the Immunoproteasome Subunit Genes, PSMB8 and PSMB10, in the MHC Class I Region of a Teleost Medaka, Oryzias latipes
Authors: K. Tsukamoto, M. Sakaizumi, M. Hata, Y. Sawara, J. Eah, C.-B. Kim, M. Nonaka
Journal: Molecular Biology and Evolution (2009)

Sequence comparison of the medaka, Oryzias latipes, major histocompatibility complex (MHC) class I region between two inbred strains, the HNI (derived from the Northern Population) and the Hd-rR (from the Southern Population), revealed a approximately 100 kb highly divergent segment encompassing two MHC class IA genes, Orla-UAA and Orla-UBA, and two immunoproteasome beta subunit genes, PSMB8 and PSMB10. To elucidate the genetic diversity of this region, we analyzed polymorphisms of the PSMB8 and PSMB10 genes using wild populations of medaka from three genetically different groups: the Northern Population, the Southern Population, and the China-West Korean Population. A total of 1,245 specimens from 10 localities were analyzed, and all the PSMB8 and PSMB10 alleles were classified into the N (fixed in the HNI strain) or the d (fixed in the Hd-rR strain) lineage. Polymerase chain reaction analysis of the region from PSMB8 to PSMB10 indicated that the two allelic lineages of these genes are segregating together constituting dichotomous haplotypic lineages. Both haplotypic lineages were identified in all three groups, although the frequency of d haplotypic lineage (73-100%) was much higher than that of N haplotypic lineage (0-27%) in all analyzed populations. The two allelic lineages of the PSMB8 gene showed curious substitutions at the 31st and 53rd residues of the mature peptide, which are likely involved in formation of the S1 pocket, suggesting that these alleles have a functional difference in cleavage specificity. These results indicate that the two medaka MHC haplotypic lineages encompassing the PSMB8 and PSMB10 genes are maintained in wild populations by a balancing selection.
Mortality and Timing of Surgery for Prosthetic Valve Endocarditis—Reply
Authors: Tahaniyat Lalani, Andrew Wang
Journal: JAMA Internal Medicine (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Mastectomy or conservation: the patient's choice: Authors' reply
Authors: P J D K Dawes, A. Hart, R C Wilson
Journal: BMJ (1988)

understood that the purpose of screening is to diagnose cancers earlier.Thus in the first year of a programme it is hoped to diagnose not only cancers that would surface spontaneously in that year but also many that would otherwise have surfaced in the second, third, and fourth years of the programme.The excess of cancers in the screened group results from the earlier diagnosis.Other evidence shows that overdiagnosis has not oc- curred in either the Health Insurance Plan study or the Swedish studies.Dr Skrabanek has a valid point that incomplete accounts of the Swedish study have been published internationally.This reflects, however, editorial reluctance to publish extensive statistical data rather than an unwillingness to publish by the investigators.Your readers, however, may find strange Dr Skrabanek's complaint that some of the results ofthe Swedish trial appeared in the Swedish literature.
STUDIES OF GONOCOCCAL INFECTION. II. THE BACTERIOLYTIC POWER OF THE WHOLE DEFIBRINATED BLOOD OF PATIENTS WITH GONOCOCCAL ARTHRITIS 1
Authors: Wesley W. Spink, Chester S. Keefer
Journal: Journal of Clinical Investigation (1937)

In the previous paper (1), we presented evidence that the bactericidal action of whole de- fibrinated blood for the gonococcus was the same as that of plasma or serum.It was demonstrated that phagocytosis of the gonococcus by the poly- morphonuclear leukocytes played little or no part in the destruction of the organisms in vitro.The experiments supported the conclusions that the gonococcus was killed in vitro by bacteriolysis, and that this was accomplished by a sensitization of the organisms by antibody; the lysis was com- pleted by the action of complement.There was no evidence that intracellular digestion of the or- ganisms by leukocytes took place, in spite of the fact that active phagocytosis could be demon- strated.We then proceeded to study the variations in the bactericidal action of the whole defibrinated blood of 29 patients with gonococcal infections.Sixteen had local infections, notably urethritis, endocervicitis, or conjuctivitis, and the remaining 13 individuals had gonococcal arthritis.